Thomas Malley has served as a member of our Board of Directors since 2016.
Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm, since 2007. Mr. Malley was with Janus Mutual Funds in positions of increasing responsibility from 1991 to 2007. From 1999 to 2007, Mr. Malley served as a portfolio manager for the Janus Global Life Sciences Fund and led its team of healthcare analysts. From 1991 to 1998, Mr. Malley was an equity analyst for Janus, covering healthcare and biotechnology stocks, among others. Mr. Malley has been a director of Kura Oncology, Inc., since 2015 and a director of Kiniksa Pharmaceuticals since 2016. He previously served as a director of OvaScience, Inc.; Synageva BioPharma Corp until its acquisition by Alexion Pharmaceuticals, Inc.; Puma Biotechnology, Inc., and Cougar Biotechnology, Inc., until its acquisition by Johnson and Johnson.
Mr. Malley holds a B.S. in biology from Stanford University.